

Molecular Haemato-Oncology Trial Schedule 2025 – 2026

| Accredited Programmes | Trial issue | APR 25 | MAY 25 | JUN 25 | JUL 25 | AUG 25 | SEP 25 | OCT 25 | NOV 25 | DEC 25 | JAN 26 | FEB 26 | MAR 26 |
|--|-------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| BCR::ABL1 and AML Translocation Identification | 3 | X | | | | X | | | | X | | | |
| BCR::ABL1 Kinase Domain Variant (Mutation) Status | 3 | | | X | | | | X | | | | X | |
| BCR::ABL1 Major Quantification | 3 | | X | | | | X | | | | X | | |
| BCR::ABL1 Minor Quantification | 3 | | X | | | | X | | | | X | | |
| BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia | 3 | X | | | X | | | | | X | | | |
| FLT3 Mutation Status | 3 | | | | X | | | | X | | | | X |
| IG/TCR Clonality Status | 3 | X | | | | X | | | | X | | | |
| KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease | 3 | | X | | | | X | | | | X | | |
| Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia | 3 | | | X | | | | X | | | | | X |
| Myeloproliferative Neoplasms Diagnostic Testing ¹ | 4 | | X | | | X | | | X | | | X | |
| NPM1 Mutation Status | 3 | | | | X | | | | X | | | | X |
| Paediatric Acute Leukaemia Translocations | 3 | | | X | | | | X | | | | X | |
| Post-Stem Cell Transplant Chimerism Monitoring | 5 | | X | | X | | | X | | X | | X | |

| Non-accredited Programmes | Trial Issue | APR 25 | MAY 25 | JUN 25 | JUL 25 | AUG 25 | SEP 25 | OCT 25 | NOV 25 | DEC 25 | JAN 26 | FEB 26 | MAR 26 |
|---|-------------|--------|--------|--------|--------|----------------|----------------|--------|--------|--------|--------|----------------|----------------|
| Lymphoid Gene Panels | 2 | | | | | | X ² | | | | | | X ³ |
| Measurable Residual Disease for Acute Myeloid Leukaemia by Molecular Methods | 2 | | | | | X | | | | | | | X |
| Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods | 2 | | | X | | | | | X | | | | |
| Myeloid Gene Panels | 2 | | | | | X ² | | | | | | X ³ | |

1. The JAK2 p.V617F mutation status and MPN DT programmes have now been merged and include testing of JAK2 p.V617F, JAK2 exon 12, CALR and MPL. Please note, only the JAK2 p.V617F aspect of testing is currently accredited. We are working towards accreditation for the other markers. 2. Includes educational variant interpretation; 3. Technical focus.

Authorised on: 19-Dec-2024. Authorised by: Stuart Scott. Document Unique Reference: view only. No review required. Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.